U.S. FDA Clears Pluristem's Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery

Stock Information for Pluristem Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pluristem Therapeutics Inc.

Pluri CEO Issues Shareholder Update
Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
Pluristem CEO Issues Shareholder Update
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.